Blood NfL as a Biomarker in Neuro Trials: Promise and Challenges

Blood NfL: A Promising Biomarker in Neurodegenerative Trials

Blood-based neurofilament light chain (NfL) is emerging as a promising biomarker in clinical trials for neurodegenerative diseases, offering a potential surrogate endpoint for disease activity and treatment response. This potential is highlighted in a recent scoping review published on July 20, 2026, which analyzed 49 studies involving conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Alzheimer's disease (AD).

NfL, a structural protein of axons, is measurable in both cerebrospinal fluid (CSF) and blood, making it a convenient marker for assessing neuroaxonal injury. Its ease of measurement in blood samples could facilitate broader application in clinical settings, potentially streamlining the monitoring of disease progression and response to treatment.

Mechanism and Context of NfL Use

Neurofilament light chain serves as an indicator of axonal damage, with elevated levels reflecting active neurodegeneration. In the reviewed studies, reductions in blood NfL levels often paralleled improvements in primary efficacy outcomes, suggesting its utility as a biomarker of disease activity. This correlation was particularly noted in conditions with active axonal injury, such as MS and ALS.

However, the review also identified variability in the concordance between changes in NfL levels and clinical outcomes. Some interventions studied did not modify the underlying disease mechanisms, which may explain the lack of consistent correlation. This highlights the need for disease- and intervention-specific interpretation of NfL data.

Implications for Clinical Trials and Research

The potential of blood NfL as a surrogate endpoint could significantly impact the design and interpretation of clinical trials. Its use could enhance the sensitivity of trials to detect treatment effects, particularly in early-phase studies where traditional clinical endpoints may be less responsive. This could accelerate the development of new therapies for neurodegenerative diseases.

However, further validation is crucial to establish the reliability of NfL as a clinical endpoint. Researchers must ensure that NfL measurements accurately reflect disease activity and that they are applicable across different neurodegenerative conditions and interventions.

Risks and Unknowns

Despite its promise, the use of blood NfL as a biomarker comes with risks and unknowns. The variability in its correlation with clinical outcomes suggests that NfL may not always be a reliable indicator of treatment efficacy. Additionally, the biological variability of NfL levels across individuals and disease states needs to be better understood.

There is also a risk of over-reliance on NfL as a biomarker, potentially overlooking other important clinical endpoints. Researchers and clinicians must balance the use of NfL with other measures to ensure comprehensive assessment of treatment effects.

Future Directions

Looking forward, the integration of blood NfL into clinical trial protocols could transform the landscape of neurodegenerative disease research. However, this will require rigorous standardization of measurement techniques and further studies to validate its utility across different conditions and interventions.

As the field progresses, collaboration between researchers, clinicians, and regulatory bodies will be essential to establish guidelines for the use of NfL as a biomarker. This will ensure that its integration into clinical practice is both scientifically sound and beneficial to patient care.